Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat various cancers. Its product candidates include immune-oncology therapies such as PYX-106 and PYX-201, which are in Phase 1 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, breast cancer, endometrial cancer, and others. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

COM:PYXISONCOLOGY

Pyxis Oncology, Inc.

Last Close

3.82

21/11 21:00

Market Cap

174.31M

Beta: -

Volume Today

15.04M

Avg: -

Analysis Not Available